血液系统疾病的放射性核素治疗。

Radionuclide therapy of hematologic disorders.

作者信息

Silberstein E B

出版信息

Semin Nucl Med. 1979 Apr;9(2):100-7. doi: 10.1016/s0001-2998(79)80041-0.

Abstract

32P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play a role in the therapy of infradiaphragmatic lymphoma. Among the radionuclides that have at times been used in hematology are 32P, 198Au 24Na, 76As, 89Sr, 52Mb, 54Mn, 91Y, 95Zr, 95Cb, 111Ag, 109Pd, 131I, 185W, and 192Ir. As stated, 32P has proven single most efficacious agent. The hematologic diseases that have been treated include both malignant and benign conditions. Among the malignant conditions are polycythemia vera, agnogenic myeloid metaplasia, thrombocythemia, leukemia, Hodgkin's disease, and multiple myeloma. Hemophilia, and Osler--Weber--Rendu disease are among the benign entities in which the agents have been tried. Polycythemia and thrombocythemia remain those in which the greatest success has been achieved.

摘要

32P是真性红细胞增多症和原发性血小板增多症的有效治疗方法。真性红细胞增多症研究小组正在比较放射性磷与烷化剂以确定相对疗效。32P与白消安在慢性粒细胞白血病中的有效性研究较少。放射性药物的内淋巴给药可能在膈下淋巴瘤的治疗中发挥作用。血液学中有时使用的放射性核素包括32P、198Au、24Na、76As、89Sr、52Mb、54Mn、91Y、95Zr、95Cb、111Ag、109Pd、131I、185W和192Ir。如前所述，32P已被证明是最有效的单一药物。已治疗的血液疾病包括恶性和良性疾病。恶性疾病包括真性红细胞增多症、原因不明的髓样化生、血小板增多症、白血病、霍奇金病和多发性骨髓瘤。血友病和遗传性出血性毛细血管扩张症是尝试使用这些药物的良性疾病。真性红细胞增多症和血小板增多症仍然是取得最大成功的疾病。